Kadimastem Ltd (TLV: KDST)

Market Cap	48.31M
Revenue (ttm)	n/a
Net Income (ttm)	-9.72M
Shares Out	4.19M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,961
Open	1,180.00
Previous Close	1,157.00
Day's Range	1,130.00 - 1,200.00
52-Week Range	430.00 - 1,420.00
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Kadimastem

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 12
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: KDST